The Heterogeneous Landscape of Head & Neck Squamous Cell Carcinomas, Head & Neck Squamous Cell CarcinomasHead and neck squamous cell carcinomas can be highly aggressive tumors in some cases, while other prognoses can be very good. The tumors present in different anatomical regions of the upper airways and digestive tract, and they present with very different mutation profiles, molecular characteristics, and immune landscapes, as well as prognoses.
Recognizing that differences in these head and neck cancers exist is important. But, the heterogeneity in head and neck squamous cell carcinomas has made it difficult to map out the immunological characteristics of these tumors in a way that will improve treatment and therefore improve patients' outcomes.
That's the bottom line from a recent review on the topic, published earlier this year online ahead of print in the journal Frontiers in Cell and Developmental Biology (2019; doi.org/10.3389/fcell.2019.00052).
“Over the past decade, despite the marked improvement in clinical outcome of many tumor types, the overall 5-year survival rate of [head and neck squamous cell carcinomas] remained [approximately] 40-50 percent largely due to poor availability of effective therapeutic options for [head and neck squamous cell carcinoma] patients with recurrent disease,” the coauthors note in the paper.
While there have been gains in better understanding the molecular characterization of head and neck squamous cell carcinomas (in terms of somatic mutations and alterations in gene expression and rearrangement), those insights have not yet been used to change treatment paradigms for these patients, according to the paper.
“There is an urgent and unmet need for the identification of specific molecular signatures that better predict the clinical outcomes and markers that serve as better therapeutic targets,” the coauthors noted. Here are some of the points made in the paper.
Classification beyond anatomical region is important, but that doesn't mean genomic analysis alone should be considered.
Conventional classification of these cancers is based on anatomic location and tumor characteristics (like stage, depth of tumor invasion, and tumor-node metastasis). But those factors alone are not enough to accurately predict prognoses, suggesting that other factors should be taken into account, according to the new review.
HPV status should be considered in these tumors. But one challenge is that HPV status has not always been considered in existing literature. “Most of the molecular classification studies were performed using total [head and neck squamous cell carcinoma] specimens regardless of HPV statuses,” the coauthors noted.
Genomic expression needs to be taken into account, as that information may inform new therapeutic targets. But classical molecular subtypes are important, too, including classical, basal, mesenchymal, and atypical subtypes, which exist across all tumor subtypes and anatomical locations. Combining that information with gene expression profiles will be important.
“Integrative genomic analyses in association with functional annotation provides valuable information for identifying molecular drivers of carcinogenesis, potential markers for prognosis, and [head and neck squamous cell carcinoma] classification based on molecular signatures that may facilitate a better prediction for responsiveness to therapy,” the review's coauthors noted.
Immune landscape of the tumor microenvironment matters, too.
Another point in the review: It's not enough to just look at what's happening in the tumor; what's happening in the immune system and how the molecules in the immune system are responding to the tumor needs to be considered, too.
There's evidence to support the significance of the immunosurveillance hypothesis that there are dynamic and bidirectional interactions between the tumor cells and the immune system that contribute to a tumor's growth and survival, according to the paper's coauthors.
“The immunosurveillance concept has been well appreciated to relay an important physiological process during carcinogenesis and tumor progression, and has provided invaluable insight into potential targets for immunotherapy intervention,” they noted, adding that bolstering immune defense is significant to improving anticancer therapy.
Checkpoint inhibitor therapy will be important, but research needs to discriminate more heavily on tumor characteristics.
Checkpoint inhibitor therapies, like anti-PD-1 and anti-CTLA4 antibodies, hold a lot of promise for improving outcomes for patients with head and neck squamous cell carcinomas (specifically many tumors are known to express PD-L1, PD-1, and CTLA-4 molecules). But previous studies may have underestimated the benefits of those studies by not classifying patients into subtypes that were discriminatory enough to show who the therapies worked for and who they did not work for.
“Early checkpoint inhibitor clinical trials for [head and neck squamous cell carcinoma] treatment did not discriminate patients based on their HPV status,” the review's coauthors noted in the paper. “As we now appreciate the high level of heterogeneity in the [tumor microenvironment] of [head and neck squamous cell carcionomas] concerning the HPV status and tumor types, it becomes clear that analyzing and presenting the [head and neck squamous cell carcinoma] clinical trial results by segregating HPV (+) patients from HPV (-) cases will be more informative.”
Recent FDA approval of pembrolizumab for some HNSCC is a step forward.
Head and neck cancers are no longer thought of as a homogeneous disease, Cristina Rodriguez, MD, an oncologist specializing in the treatment of people with head and neck, salivary gland, thyroid, and lung cancers at Seattle Cancer Care, shared with Oncology Times. Rodriguez was not involved in writing the recent review paper.
“Looking at the entire population without recognizing these differences may lead to misleading assumptions,” added Rodriguez, who is also Associate Professor at University of Washington School of Medicine and Associate Member of the Clinical Research Division at Fred Hutchinson Cancer Research Center. (Her research at Fred Hutch focuses on integrating targeted and biological therapies into multimodal therapy of locally advanced head and neck squamous cell carcinomas and optimizing functional outcomes after therapy for advanced head and neck malignancies).
One step in the right direction, Rodriguez said, is the FDA's approval of pembrolizumab either used as a monotherapy in patients with head and neck squamous cell carcinomas whose tumors express PD-L1 or in combination with a platinum and fluorouracil chemotherapy regimen for first-line treatment of patients with metastatic or unresectable tumors. Pembrolizumab is a PD-1 inhibitor, a type of immunotherapy, and has previously been approved for the treatment of other cancers, including lung and skin cancers.
“Since the great majority of patients with head and neck squamous cell carcinomas are diagnosed with locally advanced, potentially curable disease, investigating the incorporation of immune checkpoint inhibitors in the curative-intent setting would have a major impact on the treatments we offer our patients,” she stated. “The landscape of treatment is rapidly shifting.”
The bottom line she believes oncologists should know about treating patients with head and neck cancers is that, to provide treatment with the best oncologic and functional outcomes, tailoring therapy to the individual and the characteristics of his or her disease is increasingly important.
“One of the most important aspects of formulating these treatment plans is the multidisciplinary clinic, and I cannot emphasize how important the input of the many specialists who treat head and neck cancer is to ensure the best treatment outcomes for our patients,” she said.
Sarah DiGiulio is a contributing writer.
|
Finding a Cure for Children With CNS Neuroblastoma No abstract available |
EHR Tool Finds Pediatric Leukemia Patients for Clinical Studies No abstract available |
In Search of an Immunotherapy Innovation for Ovarian Cancer No abstract available |
Childhood Leukemia Cannot Hide From Immune System No abstract available |
UpToDate® No abstract available |
Enzalutamide Improved Survival in Metastatic Prostate Cancer No abstract available |
Olaparib Improved Outcomes in BRCA-Mutated Metastatic Pancreatic Cancer No abstract available |
Dual Targeted Immune Activation in Gynecological Cancer No abstract available |
Targeted Therapies in Elderly Patients With Metastatic Renal Cell Carcinoma No abstract available |
ΩτοΡινοΛαρυγγολόγος Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,
Translate
Ετικέτες
Δευτέρα 5 Αυγούστου 2019
Αναρτήθηκε από
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
στις
11:11 μ.μ.
Ετικέτες
00302841026182,
00306932607174,
alsfakia@gmail.com,
Anapafseos 5 Agios Nikolaos 72100 Crete Greece,
Medicine by Alexandros G. Sfakianakis
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Αρχειοθήκη ιστολογίου
-
►
2023
(278)
- ► Φεβρουαρίου (139)
- ► Ιανουαρίου (139)
-
►
2022
(1962)
- ► Δεκεμβρίου (107)
- ► Σεπτεμβρίου (158)
- ► Φεβρουαρίου (165)
- ► Ιανουαρίου (163)
-
►
2021
(3614)
- ► Δεκεμβρίου (152)
- ► Σεπτεμβρίου (271)
- ► Φεβρουαρίου (64)
- ► Ιανουαρίου (357)
-
►
2020
(3279)
- ► Δεκεμβρίου (396)
- ► Σεπτεμβρίου (157)
- ► Φεβρουαρίου (382)
- ► Ιανουαρίου (84)
-
▼
2019
(11718)
- ► Δεκεμβρίου (265)
- ► Σεπτεμβρίου (545)
-
▼
Αυγούστου
(750)
- Medicine by Alexandros G. Sfakianakis,Anapafseos 5...
- Inflammation
- Radiology
- Programmed chromosome fission and fusion enab...
- Distinct immunology of the placenta
- Topography of the central retinal artery rele...
- No ‘gay gene’: Massive study homes in on gen...
- American Journal of Primatology
- Dermatological and Epidemiological Profiles ...
- Reply to Dr. Suga and Dr. Takenoshita Abstr...
- Με αυτό τον τρόπο το παιδί δεν θα εκδηλώσει ...
- Legends of Allergy and Immunology: Donald Y....
- The use of aggregation-induced emission prob...
- Αυτό το παυσίπονο αυξάνει τον κίνδυνο υπογλυ...
- VASCULARITY TARGETED PERCUTANEOUS ETHANOL IN...
- Leucine depletion extends the lifespans of l...
- Trends in Mortality From Human Immunodeficien...
- Associations between cerebrovascular risk fa...
- Stem Cells in the Treatment of Disease New E...
- Head and Neck
- British Journal of Oral and Maxillofacial Sur...
- Cancer Science
- Clinical Anatomy
- Medicine by Alexandros G. Sfakianakis,Anapafseos 5...
- Nanomaterials, Vol. 9, Pages 1218: Fabrica...
- Medicina, Vol. 55, Pages 547: Total Serum ...
- International Journal of Environmental Resear...
- Arts, Vol. 8, Pages 111: The Persistence o...
- Arbuscular mycorrhiza and plant chromium toleran...
- Adenine decreases hypertrophic effects through i...
- Degradation of 17α-ethinylestradiol by Enterobac...
- Special issue on Intelligence Computation Evolut...
- A nonlinear state marginal price vector model fo...
- What's new in academic International medicine? T...
- Mādhyamikas Playing Bad Hands: The Case of Custo...
- Microporous scaffolds support assembly and diffe...
- The Gender Gap in Globalization and Well-Being A...
- Evaluation of a trap-and-transport program for a...
- Proceedings of the Royal Society B, Vol. 286, ...
- Nuclear Medicine and Molecular Imaging, FDG PET...
- Experimental DermatologyVolume 28, Issue 9Pages:...
- Understanding Connection Between Poverty, Child...
- Surveillance efficiency evaluation of air qualit...
- Opioid Prescribing Can Be Reduced in Oral and Ma...
- Exploring How Pediatric Residents Develop Adapti...
- Perceptions of Sexual Harassment in Oral and Max...
- Comparative Efficacy of 35% Glycolic Acid Peel A...
- The impact of a complex consulting process with ...
- Oropharyngeal recovery in a patient with the phar...
- Platelet-rich plasma protocols can potentiate vas...
- Relationship between Obesity and Balance in the ...
- Dabigatran for catastrophic antiphospholipid syn...
- Recovery of left ventricular twist and left vent...
- Don't Panic, Scientists Haven't Shown C-Section...
- USDA food safety leaders By Dan Flynn on Aug 29,...
- cGMP Signaling and Modulation in Heart FailureCy...
- SAGE Cardiology and Cardiovascular Medicine hu...
- A clinical comparative study of four interocclus...
- Global vascular guidelines on the management of ...
- Wound Repair and RegenerationEarly View Online...
- The ellipselet transformZahra Khodabandeh, Hosse...
- Public Health Law News Announcements...
- Determining the Association Between End-of-Life ...
- Incidence and risk factors of postoperative deli...
- Prognostic predictions based on pathological fin...
- Public Health Policies on E-Cigarettes Abstract ...
- Comparison of drug-eluting balloon with repeat d...
- What will surgical coronary revascularization lo...
- Anaesthetic considerations in nonagenarians and ...
- The statement of the Asia-Pacific Association fo...
- Duration of allergen immunotherapy for inhalant ...
- Transcranial Shear Wave Elastography of Neonatal...
- Effects of adjuvant mental practice using invers...
- Evidence-Based Use of Perioperative Antibiotic...
- Associations of awake and asleep blood pressure ...
- Diagnostic ‘nightmares’ in an HIV patient with a...
- Comparison of Commercial Enzyme-Linked Immunos...
- Archives of Disease in Childhood
- Segmental arterial mediolysis (SAM) is a nonathero...
- Cardiac MRI,
- Methods Used to Maximize Follow-up: Lessons Lear...
- Memories of Donald Dean Trunkey, Life-Saving Int...
- Building Blocks for Addressing Social Determin...
- Magnetic Resonance Imaging for the Follow-up of ...
- Pakistan Journal of Biological Sciences - Curre...
- Current Status and Future of Robotic Colorectal ...
- Daily Functioning in Schizophrenia: Is There Roo...
- Home-Based Cardiac Rehabilitation: A SCIENTIFIC...
- Obstructive Sleep Apnea and Primary Open-angle G...
- Correcting a Deficiency: Furthering Our Knowledg...
- Immunosuppression and Graft Rejection in Living-...
- American Journal of Orthodontics and Dentofacial O...
- The Pediatric Home Health Care Process: Perspe...
- ► Φεβρουαρίου (1143)
- ► Ιανουαρίου (744)
-
►
2017
(2)
- ► Φεβρουαρίου (1)
- ► Ιανουαρίου (1)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου